FDA Approves New Targeted Breast Cancer Drug

By: Associated Press Email
By: Associated Press Email

WASHINGTON (AP) - The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones.

The drug Kadcyla (kad-SY'-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy and a third chemical linking the medicines together. The chemical keeps the drugs intact until they bind to a cancer cell, where the double-shot of medication is released.

The FDA approved the drug for about 20 percent of breast cancer patients who have a particular form of the disease. These patients have tumors that overproduce the protein HER-2.

The approval will help Roche build on the success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of $6 billion last year.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
KOLO-TV 4850 Ampere Drive Reno, NV 89502
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 192496351 - kolotv.com/a?a=192496351
Gray Television, Inc.